R R

What Is the Success Rate of Keratolimboplasty?

Keratolimboplasty can successfully rebuild a stable corneal surface in many patients with severe limbal stem cell deficiency, but published results vary widely according to the underlying eye condition and how long patients are followed. A 2024 review found that keratolimbal graft survival ranged from 21% to 90% across studies with follow-up periods of 12 to 95 months, while improved best-corrected vision was reported in 42% to 92% of treated eyes. In a separate study of 49 eyes, about 71% of grafts were still successful at the final follow-up, and the estimated three-year survival rate was approximately 71%. Long-term results can decline, with another study reporting that functional walking-around vision was maintained in about 54% of eyes after three years and 45% after five years. Outcomes tend to be better when eye-surface inflammation, eyelid problems, and severe dryness are controlled and patients consistently follow their prescribed immunosuppressive treatment, with stable ocular-surface rates of roughly 70% to 80% reported among patients who stayed on long-term therapy.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is the Success Rate of Keratolimboplasty?

Keratolimboplasty can successfully rebuild a stable corneal surface in many patients with severe limbal stem cell deficiency, but published results vary widely according to the underlying eye condition and how long patients are followed. A 2024 review found that keratolimbal graft survival ranged from 21% to 90% across studies with follow-up periods of 12 to 95 months, while improved best-corrected vision was reported in 42% to 92% of treated eyes. In a separate study of 49 eyes, about 71% of grafts were still successful at the final follow-up, and the estimated three-year survival rate was approximately 71%. Long-term results can decline, with another study reporting that functional walking-around vision was maintained in about 54% of eyes after three years and 45% after five years. Outcomes tend to be better when eye-surface inflammation, eyelid problems, and severe dryness are controlled and patients consistently follow their prescribed immunosuppressive treatment, with stable ocular-surface rates of roughly 70% to 80% reported among patients who stayed on long-term therapy.

read more about Keratolimboplasty ...

Copy this HTML:

Copy HTML Copied!

Who Is a Good Candidate for Limbal Stem Cell Transplant Surgery?

A good candidate for limbal stem cell transplant surgery has confirmed limbal stem cell deficiency that has caused persistent corneal clouding, abnormal blood vessel growth, recurring surface breakdown, or reduced vision despite medical treatment. Keratolimbal allograft surgery is mainly considered when both eyes are affected or when taking tissue from the patient's other eye would place that healthy eye at unnecessary risk. Before surgery, inflammation should be brought under control, while severe dry eye, eyelid abnormalities, infections, and exposure problems should be treated because an unstable ocular surface can reduce the chance of graft survival. Candidates must also be healthy enough to take long-term systemic immunosuppressive medication, since donor limbal tissue can be rejected without continued immune control. A corneal specialist will confirm the severity and extent of the deficiency before deciding whether transplantation is appropriate, since partial disease can sometimes be managed with less extensive procedures.

What Happens During the Keratolimbal Graft Procedure?

During a keratolimbal graft procedure, the surgeon first removes the abnormal conjunctival tissue, scarred surface cells, and blood vessels that have grown across the cornea, creating a cleaner surface for the transplant. Donor corneoscleral tissue containing healthy limbal stem cells is then carefully trimmed into thin graft segments, with tissue from two donor rims commonly used to rebuild the full 360-degree border of the damaged cornea. These segments are positioned around the limbus and secured with fine sutures, and an amniotic membrane can also be placed over the eye to protect the surface while new epithelial cells begin spreading across it. The procedure is intended to restore a stable, continuously healing corneal surface rather than immediately remove deeper corneal scarring, so a separate corneal transplant can be scheduled later when clearer vision requires it. Because the implanted cells come from donor tissue, systemic immunosuppressive treatment is generally started around the time of surgery and continued afterward to lower the risk of rejection.

How Long Does Recovery Take After Surgery?

Recovery after keratolimboplasty takes place in stages, with the first few weeks focused on closing the corneal surface and protecting the newly transplanted stem cells. In a small clinical series, four of five treated eyes developed a complete surface layer within one month, although larger defects or severe preexisting damage can extend that timeline. Temporary eyelid-closing sutures can remain in place for about two weeks, while anti-inflammatory eye treatment may be tapered over two to three months once the surface appears calm. In one long-term study, patients who later needed a separate corneal transplant waited an average of 9.6 months after keratolimbal surgery, giving the ocular surface time to stabilize before the next operation. Full recovery can therefore take several months and requires frequent follow-up, since dryness, eyelid problems, inflammation, or recurring epithelial defects can slow healing even after the initial surgical wound has closed.

Signs That the Transplanted Tissue Is Not Healing Properly

Signs that transplanted limbal tissue is not healing properly include a corneal surface that stays open, repeatedly breaks down, or develops areas that do not form a smooth and stable epithelial layer. New blood vessels or conjunctival tissue growing back across the normally clear cornea can signal that limbal stem cell deficiency is returning and the graft is losing control of surface renewal. Graft rejection can produce pronounced redness around one section or across the eye, along with swelling and inflammatory deposits within the transplanted tissue. Persistent epithelial defects also leave the eye more vulnerable to microbial keratitis, which can cause worsening pain, light sensitivity, corneal clouding, and reduced vision. Any new or intensifying symptoms after surgery need prompt examination because rejection, infection, and surface failure require different treatment approaches.

Frequently Asked Questions About Keratolimboplasty

Does Keratolimboplasty restore clear vision right away?

Not necessarily. The first goal is to rebuild a stable corneal surface, and vision can remain limited when deeper scarring or other eye damage is still present.

Where does the transplanted limbal tissue come from?

Keratolimbal allograft tissue is taken from a deceased donor and includes limbal stem cells attached to a thin corneoscleral rim. This approach avoids removing tissue from the patient's healthier eye, which is especially helpful when both eyes are affected.

How long is immunosuppressive medication needed after surgery?

The medication schedule varies according to inflammation, healing, and rejection risk. In one published treatment protocol, corticosteroids were tapered within three to six months, while other immune-suppressing medications were continued for as long as 18 to 24 months.

Will another corneal surgery be needed later?

Some patients need a separate corneal transplant after the surface has stabilized, especially when deeper corneal scarring continues to block vision. In one study of combined limbal transplantation, about 79% of treated eyes later underwent a staged corneal transplant.

References

Adverse Effects of Systemic Immunosuppression in Keratolimbal Allograft. Journal of Ophthalmology / Hindawi. https://pmc.ncbi.nlm.nih.gov/articles/PMC3317135/. Published February 28, 2012. Accessed July 16, 2026.

Keratolimbal Allograft. Current Opinion in Ophthalmology / Wolters Kluwer. https://pubmed.ncbi.nlm.nih.gov/28379858/. Published July 1, 2017. Accessed July 16, 2026.

Long-Term Outcome of Keratolimbal Allograft With or Without Penetrating Keratoplasty for Total Limbal Stem Cell Deficiency. Ophthalmology / Elsevier. https://pubmed.ncbi.nlm.nih.gov/12045060/. Published June 1, 2002. Accessed July 16, 2026.

Long-Term Outcomes of Keratolimbal Allograft for Total Limbal Stem Cell Deficiency Using Combined Immunosuppressive Agents and Correction of Ocular Surface Deficits. Archives of Ophthalmology / American Medical Association. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/424366. Published November 1, 2009. Accessed July 16, 2026.

Long-Term Outcomes of Ocular Surface Stem Cell Allograft Transplantation. American Journal of Ophthalmology / Elsevier. https://pubmed.ncbi.nlm.nih.gov/29032107/. Published December 1, 2017. Accessed July 16, 2026.

Outcome of Keratolimbal Allograft Transplantation With Deep Anterior Lamellar Keratoplasty for Bilateral Limbal Stem Cell Deficiency. Frontiers in Medicine / Frontiers Media. https://pmc.ncbi.nlm.nih.gov/articles/PMC9705574/. Published November 9, 2022. Accessed July 16, 2026.

Outcomes and Complications of Limbal Stem Cell Allograft Transplantation: A Report by the American Academy of Ophthalmology. Ophthalmology / Elsevier. https://pubmed.ncbi.nlm.nih.gov/38678469/. Published April 27, 2024. Accessed July 16, 2026.

Systemic Immunosuppression in Limbal Stem Cell Transplantation: Best Practices and Future Challenges. Canadian Journal of Ophthalmology / Elsevier. https://pubmed.ncbi.nlm.nih.gov/30119783/. Published January 20, 2018. Accessed July 16, 2026.